Disruptive Technology Channel Shares of Verve Therapeutics Up 84% in Past Month; Get Exposure With ARKG By Elle CarusoJuly 26, 2022
Disruptive Technology Channel Everything Advisors Need to Know About ARKG’s Q2 Performance By Elle CarusoJuly 21, 2022
Disruptive Technology Channel ARK to Close Passive Transparency ETF, CTRU By Elle CarusoJuly 20, 2022
Disruptive Technology Channel ARKG Increases Over 36% as Biotech’s Rebound Enters Second Month By Elle CarusoJuly 13, 2022
Disruptive Technology Channel Small-Caps’ Comeback Advantageous for Active Managers By Elle CarusoJuly 8, 2022
Disruptive Technology Channel ARKG Leads in 1-Week Returns as Biotech Rebounds By Elle CarusoJune 29, 2022
Expert Insights Chart of the Week: Advisors Remain Confident in Disruptive Innovation By Todd RosenbluthJune 23, 2022
Disruptive Technology Channel Get Exposure to the Genomic Revolution With ARKG By Elle CarusoJune 9, 2022
Disruptive Technology Channel An Innovative ETF Opportunity That Taps Into Our Increased Understanding of the Human Genome By Max ChenJune 8, 2022
Disruptive Technology Channel Change the DNA of Your Portfolio: Growth Opportunities Through Genomics By Max ChenJune 7, 2022
Disruptive Technology Channel Investors Flock to ARKK; Fund Sees $658 Million in May Inflows By Elle CarusoJune 3, 2022
Disruptive Technology Channel Some ARKG Components Could Lead in Genetic Testing By Tom LydonJune 1, 2022
Disruptive Technology Channel Why Investors Should Consider ETFs That Target Innovation Platforms By Max ChenApril 27, 2022
Disruptive Technology Channel Refining Your Innovation Exposure: How to Access Tomorrow’s Opportunities By Max ChenApril 26, 2022
Disruptive Technology Channel One of ARK Invest’s Favorite Stocks Offers Big Rebound Potential By Tom LydonApril 8, 2022
Disruptive Technology Channel Disruptive Tech ETFs Rally on Encouraging Dialogue Between Russia and Ukraine By Max ChenMarch 29, 2022
